Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 31 Jan 2006 |
| Novo Nordisk, preliminary announcement of annual report | 27 Jan 2006 |
| Novo Nordisk, Status re Novo Nordisk's holding of its own shares (31 December 2005) | 3 Jan 2006 |
| Novo Nordisk, Novo Nordisk receives subpoena in the US | 20 Dec 2005 |
| Novo Nordisk, promising clinical results from liraglutide phase 2b study | 25 Nov 2005 |